Concepedia

Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy

Suthinee Ithimakin, Pathra Theeratrakul, Apirom Laocharoenkiat, Akarin Nimmannit, Charuwan Akewanlop, Nopadol Soparattanapaisarn, Sirisopa Techawattanawanna, Krittiya Korphaisarn, Pongwut Danchaivijitr

Supportive Care in Cancer · 2020 · 27 citations · 14 references

DOI

Concepts

References

14

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 776 citations

, , +17

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 465 citations

, , +17

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy et al. · New England Journal of Medicine · 2016 · 450 citations · Full text

, , +14

Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial

Rudolph M. Navari, Sarah E. Gray, Andrew C. Kerr · The Journal of Supportive Oncology · 2011 · 316 citations

, , +17

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index?Emesis (FLIE) with 5-day recall

Beilei Cai, M. Elmer, Celeste Lindley et al. · Supportive Care in Cancer · 2003 · 141 citations

, , +17